ANI Pharma (ANIP) Misses Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
March 15, 2022 6:50 AM EDT-- Fourth quarter net revenues of $60.9 million; net loss of $24.1 million and diluted loss per share of $1.72 --
-- Fourth quarter adjusted non-GAAP EBITDA of $16.2 million and adjusted non-GAAP diluted earnings per share of $0.54 --
-- Full year 2021 revenues of $216.1 million; net loss of $42.6 million and adjusted non-GAAP EBITDA of $64.8 million --
-- Launched Purified Cortrophin Gel for the treatment of certain chronic autoimmune disorders --
-- Experienced Rare Disease leadership and team in place to drive successful commercial launch of... More
